Understand the source comparison
The Mechanism SLU-PP-332 Actually Uses vs What's Claimed
SLU-PP-332 is a selective agonist of estrogen-related receptors alpha and gamma (ERRα/γ). Nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. When activated, these receptors upregulat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SLU-PP-332 is a selective agonist of estrogen-related receptors alpha and gamma (ERRα/γ). Nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. When activated, these receptors upregulate PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial function and the same pathway triggered by endurance exercise. The Nature study showed that sedentary mice treated with SLU-PP-332 exhibited increased running endurance, enhanced oxygen consumption, and elevated expression of oxidative metabolism genes. Outcomes typically requiring weeks of progressive training stimulus.
- Here's where ss-lup-332 myths cost money health: the mechanism does not create endurance capacity out of nothing. It primes the cellular machinery for adaptation by increasing mitochondrial density and oxidative enzyme expression, but those adaptations only translate to functional performance when paired with actual metabolic demand. A sedentary mouse on SLU-PP-332 runs longer because the compound induced mitochondrial proliferation that gets recruited when the mouse is forced to run. Remove the exercise stimulus and the adaptation pathway stalls. The molecule doesn't burn fat directly. It shifts substrate preference toward fat oxidation when energy demand exists.
- The myth that SLU-PP-332 replicates training without effort comes from misreading the study design. Mice were tested on forced running protocols. The compound allowed them to sustain higher workloads, not perform better at rest. Translating that to humans means the compound might enhance training adaptation or recovery capacity, not replace the training itself. Researchers designing protocols around 'exercise-free metabolic enhancement' are setting up studies with null hypotheses that the actual pharmacology can't support. At Real Peptides, we've seen procurement requests for SLU-PP-332 accompanied by study designs that expect fat loss outcomes without exercise intervention. Those studies fail because the mechanism requires cellular energy flux to activate.